retatrutide clinical trials safety efficacy VisualAbstract: reduces body weight by 17.5% in patients with obesity Retatrutide, an Amazing Future for

This multi-target mechanism could lead to improved outcomes and offer hope for individuals who do not respond well to existing treatments

Together, we unpack the why behind your interest in weight loss or GLP-1 use

[1] [3] Key safety considerations include: Bleeding risk assessment : Ensure patients understand signs of bleeding (unusual bruising, blood in urine or stools, prolonged bleeding from cuts) and when to seek help Medication adherence : Address any gastrointestinal side effects promptly to prevent non-adherence to either medication Hydration status : Gastrointestinal adverse effects may cause dehydration, which can affect renal function and potentially impact DOAC clearance or increase risk of acute kidney injury Injection site management : Patients should rotate Ozempic injection sites and avoid injecting into areas with bruising or active bleeding Pancreatitis awareness : Stop Ozempic and seek urgent medical attention if severe persistent abdominal pain radiating to the back occurs Diabetic retinopathy monitoring : Particularly important in patients with pre-existing retinopathy Hypoglycaemia risk : Increased when Ozempic is used with insulin or sulfonylureas Patient education is paramount

If needed, attempt a second bathroom visit during the afternoon motility window (2 hours after lunch)